You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 11, 2025

Patent: 10,280,230


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,280,230
Title:Use of human cells of myeloid leukemia origin for expression of antibodies
Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
Inventor(s): Goletz; Steffen (Berlin, DE), Danielczyk; Antje (Berlin, DE), Baumeister; Hans (Berlin, DE), Stahn; Renate (Berlin, DE), Loeffler; Anja (Eichhorst, DE), Stoeckl; Lars (Berlin, DE)
Assignee: Glycotope GmbH (Berlin, DE)
Application Number:14/703,498
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive Analysis of United States Patent 10,280,230: A Deep Dive into Claims and Patent Landscape

Introduction

United States Patent 10,280,230, like any other patent, is a complex document that requires a thorough analysis to understand its implications, strengths, and weaknesses. This analysis will delve into the key components of the patent, including its claims, the legal framework governing its validity, and the broader patent landscape.

Understanding the Patent Claims

Claim Structure

Patent claims are the heart of any patent, defining the scope of the invention and what is protected. For U.S. Patent 10,280,230, it is crucial to analyze each claim type:

  • Independent Claims: These claims stand alone and define the invention without reference to other claims.
  • Dependent Claims: These claims refer back to and further limit the independent claims, often adding specific details or narrowing the scope[3].

Claim Analysis

To analyze the claims of U.S. Patent 10,280,230, one must consider the following:

  • Section 101: Patentable Subject Matter: Ensure the claims fall within the categories of patentable subject matter as defined by 35 U.S.C. § 101. This includes processes, machines, manufactures, or compositions of matter, and excludes laws of nature, natural phenomena, and abstract ideas unless the claim includes additional elements that transform the nature of the claim[3].
  • Section 102: Novelty: The claims must be novel, meaning they must not be anticipated by prior art. This involves a thorough prior art search and analysis to ensure the invention is new and not obvious in light of existing knowledge[3][4].
  • Section 103: Non-Obviousness: The claims must also be non-obvious, meaning they must represent a significant improvement over existing technology. This requires demonstrating that the invention is more than a combination of prior art elements[3].

Legal Framework and Patentability

Sections 101, 102, and 103 of U.S. Patent Law

  • Section 101: As mentioned, this section determines what constitutes patentable subject matter. The Supreme Court's decision in Alice Corp. v. CLS Bank International (2014) provides a structured test to determine eligibility, which involves identifying whether the claim is directed to a judicial exception and if it includes additional elements that transform the claim[3].
  • Section 102: This section deals with novelty and the loss of the right to a patent. It includes provisions such as the first-to-file rule under the America Invents Act (AIA) and the concept of prior art. For patents filed before the AIA, pre-AIA 35 U.S.C. § 102(g) applies, which involves interference practice and determining whether another inventor made the invention first and did not abandon, suppress, or conceal it[4].
  • Section 103: This section addresses non-obviousness. The claims must demonstrate a significant improvement over prior art, and the analysis involves determining whether the invention would have been obvious to a person of ordinary skill in the relevant field[3].

Prior Art Analysis

Conducting a Thorough Search

To ensure the novelty and non-obviousness of the claims in U.S. Patent 10,280,230, a comprehensive prior art search is essential. This can be done using various tools and resources:

  • Patent Public Search: The USPTO's Patent Public Search tool provides enhanced access to prior art and is a powerful resource for searching existing patents and published patent applications[5].
  • Global Dossier: This service allows users to access the file histories of related applications from participating IP Offices, which can help in identifying potential prior art and understanding the global patent landscape[5].
  • Patent and Trademark Resource Centers (PTRCs): These centers offer local search resources and training in patent search techniques, which can be invaluable in conducting a thorough prior art search[5].

Interpreting Legal Precedents

Case Law and USPTO Guidelines

Understanding the legal precedents and ongoing interpretations is crucial for the validity of the patent. Cases like Alice Corp. v. CLS Bank International and guidelines from the USPTO help in aligning the patent claims with the current legal landscape. Regular engagement with case law ensures that the claims are drafted in a way that complies with the latest judicial interpretations[3].

Strategic Claim Drafting

Balancing Broadness and Specificity

Drafting claims that are broad enough to offer substantial protection yet specific enough to circumvent prior art is a delicate balance. The claims must be clear, concise, and fully supported by the description. This involves highlighting the unique aspects of the invention that render it eligible, novel, and non-obvious[3].

Effective Argumentation

Building Compelling Arguments

Building compelling arguments around eligibility, novelty, and non-obviousness is crucial. This involves explaining the technological advancements brought about by the invention and distinguishing it clearly from the existing state of the art. Effective argumentation can significantly impact the success of the patent in both examination and potential litigation[3].

The Broader Patent Landscape

Global Implications

Understanding the global patent landscape is essential for any patent. Tools like the Global Dossier and databases from international intellectual property offices (such as the European Patent Office and Japan Patent Office) help in visualizing the patent family and identifying potential global prior art[5].

Conclusion

Analyzing U.S. Patent 10,280,230 involves a multifaceted approach that includes understanding the claims, the legal framework governing patentability, conducting thorough prior art searches, interpreting legal precedents, and strategically drafting claims. By integrating these elements, one can ensure that the patent stands strong in the face of scrutiny and contributes meaningfully to the broader patent landscape.

Key Takeaways

  • Claims Analysis: Ensure claims comply with Sections 101, 102, and 103 of U.S. Patent Law.
  • Prior Art Search: Conduct a comprehensive search using various USPTO tools and resources.
  • Legal Precedents: Align claims with current legal interpretations and case law.
  • Strategic Drafting: Balance broadness and specificity in claim drafting.
  • Global Considerations: Understand the global patent landscape to ensure international validity.

FAQs

Q1: What are the key sections of U.S. Patent Law relevant to patent claims?

The key sections are 101 (patentable subject matter), 102 (novelty), and 103 (non-obviousness) of U.S. Patent Law.

Q2: How do I conduct a thorough prior art search for a patent?

Use tools like the USPTO's Patent Public Search, Global Dossier, and resources from Patent and Trademark Resource Centers (PTRCs) to conduct a comprehensive prior art search.

Q3: What is the significance of the Alice Corp. v. CLS Bank International decision in patent law?

The Alice Corp. v. CLS Bank International decision established a structured test to determine the eligibility of subject matter for patenting, particularly in relation to abstract ideas and judicial exceptions.

Q4: How important is it to align patent claims with current legal interpretations and case law?

Aligning patent claims with current legal interpretations and case law is crucial to ensure the validity and enforceability of the patent.

Q5: What are the benefits of using the Global Dossier service in patent searching?

The Global Dossier service provides access to the file histories of related applications from participating IP Offices, helping to identify potential prior art and understand the global patent landscape.

Sources

  1. U.S. Patent and Trademark Office (USPTO) | USAGov
  2. U.S. Patent Small Claims Court | ACUS
  3. Exploring Sections 101, 102, & 103 of U.S. Patent Law | TT Consultants
  4. Pre-AIA 35 U.S.C. 102(g) - USPTO
  5. Search for patents - USPTO

More… ↓

⤷  Try for Free

Details for Patent 10,280,230

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Microbix Biosystems Inc. KINLYTIC urokinase For Injection 021846 January 16, 1978 10,280,230 2035-05-04
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 October 21, 1942 10,280,230 2035-05-04
Takeda Pharmaceuticals U.s.a., Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 March 03, 1954 10,280,230 2035-05-04
Csl Behring Ag ALBURX albumin (human) Injection 102366 July 23, 1976 10,280,230 2035-05-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.